| Literature DB >> 31951523 |
Erin E Longbrake1, David A Hafler2.
Abstract
Progressive multiple sclerosis (PMS) causes slow accumulation of neurologic disability and has been refractory to treatment with the immunomodulatory medications that effectively control relapsing MS. Siponimod modestly slowed the rate of disability progression among PMS patients who had inflammatory disease activity, evidenced by new or gadolinium-enhancing MRI lesions. To view this Bench to Bedside, open or download the PDF.Entities:
Mesh：
Substances：
Year: 2019 PMID： 31951523 PMCID： PMC8023412 DOI： 10.1016/j.cell.2019.11.034
Source DB: PubMed Journal: Cell ISSN： 0092-8674 Impact factor: 41.582